Merck eyes more acquisitions for life science after USD 600M Mirus Bio deal
Merck also said it will intensify the in licensing of drug candidates in its Healthcare division.
Written By : Farhat Nasim
Published On 2024-10-20 04:45 GMT | Update On 2024-10-20 04:45 GMT
Gdansk: German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for $600 million, it said ahead of its Capital Markets day on Thursday.
"Our guiding principle is and always has been, the right target, at the right time, for the right price," CEO Belen Garijo said in a statement.
"For larger future transactions, Merck is focusing on the Life Science business sector," the firm added.
Shares in the group were up 6.06% at 0727 GMT. ODDO BHF analyst Oliver Metzger attributed the move chiefly to gains in German pharma peer Sartorius, whose shares jumped 13% on Thursday after it said it expects an improved second half.
Merck narrowed expectations for its Life Science business, aiming for annual organic sales growth in a 7-9% range from a previously anticipated 7-10%.
It also said it will intensify the in-licensing of drug candidates in its Healthcare division.
The Hesse-based company changed its outlook for its Healthcare business to "slight growth", compared to a previously expected mid-single-digit percentage range, due to "recently announced pipeline setbacks", the statement said.
Merck has reported a string of setbacks in the development of cancer and multiple sclerosis drugs in recent years.
The company however raised the mid-term outlook for its electronics division to a 5-9% range from a previous 3-6%, benefiting from high demand for chips for AI applications.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.